Evidence-based therapies remain underutilized in eligible patients
MONDAY, Oct. 6, 2025 (HealthDay News) — The lifetime risk for heart failure has increased to 24 percent, according to a report published online Sept. 22 in the Journal of Cardiac Failure.
Gregg C. Fonarow, M.D., from the University of California in Los Angeles, and colleagues from the Heart Failure Society of America updated the annual report Heart Failure Epidemiology and Outcomes Statistics. The writing group members reviewed available published data regarding U.S. trends in heart failure epidemiology, incidence, and prevalence. They also looked at rates of heart failure and all-cause mortality and hospitalizations, along with differences by sex, race/ethnicity, and age.
The group reports that the prevalence of heart failure is expected to rise to 8.7 million in 2030. Both age-adjusted heart failure incidence and prevalence are higher among Black individuals versus other racial and ethnic groups. Nearly one in four individuals will develop heart failure in their lifetime. Heart failure contributed to 45 percent of cardiovascular deaths in the United States in 2022. Black, American Indian, and Alaska Native individuals have the highest all-cause, age-adjusted heart failure mortality rates of any racial and ethnic groups. Managing heart failure is costly, with projected estimated total heart failure-related expenses reaching $858 billion by 2050. Fewer than one in four eligible patients with heart failure and reduced ejection fraction receive quadruple guideline-directed medical therapy.
“Heart failure is a growing epidemic affecting millions of individuals across all demographics,” Fonarow said in a statement. “With a surge in mortality and continued underutilization of evidence-based therapies, it is imperative to prioritize improvements in the prevention, diagnosis, and treatment of heart failure.”
Cardiovascular Risk Factors, Disease Prevalence Set to Increase Through 2050 in Women
Male Sex, Older Age Predict Poor Outcomes in Seniors With HFmrEF/HFpEF
Men Have Higher Risk, Earlier Onset of Premature Cardiovascular Disease
Clonal Hematopoiesis of Indeterminate Potential Linked to CVD Risk
Eye Clinicians Identify Features of Vitreoretinal Lymphoma Presentation
Subset of Patients With Follicular Lymphoma Can Achieve Cure With CHOP-Based Chemoimmunotherapy
Comparable Progression Risk Seen With Ablation Versus Surgery for T1a Renal Cell Carcinoma
Health Consequences Vary by Chemo Regimen in Testicular Cancer Survivors